Abstract
Introduction
Chronic myelogenous leukemia (CML) is a rare blood cancer; nonetheless, CML
treatments garner substantial revenues. Despite recent advances in the
treatment of this disease (most notably, targeted therapeutics such as
Novartis' s Gleevec/Glivec [imatinib]), signifi cant unmet needs remain because
certain segments of the CML patient population are intolerant of or become
resistant to existing therapies. Emerging therapies that focus on the unmet
needs of current therapeutics have a good chance of replicating Gleevec' s
success.
Questions Answered in This Report
- Properly diagnosing CML is an integral part of choosing a " n effective
treatment. How is CML diagnosed?
- What role does genetic testing play in developing and deploying drugs for
CML? What are the symptoms of CML?
- Treatment options for CML are more targeted today than in recent history.
How was CML previously treated? Why have targeted therapies proved to be
better CML treatment options?
- Despite treatment advances, opportunities remain for emerging CML agents.
What are these opportunities? Are the opportunities potentially lucrative
enough to motivate drug developers?
Scope
- Disease overview: disease causes and indicators, physical and genetic
symptoms, diagnosis, classifi cation, epidemiology, and disease progression.
- Current CML therapies: chemotherapy, interferon-alpha, targeted therapies,
stem cell therapy.
- Emerging CML therapies: targeted therapies, therapies focused on
particular disease mutations.
- Market outlook: 2008 CML market sales, opportunities for current and
emerging CML therapies.
Mentioned in This Report
- Bristol-Myers Squibb
- ChemGenex Pharmaceuticals
- CytRx
- Deciphera Pharmaceuticals
- Exelixis
- Genzyme Genetics
- Innate Pharma
- Janssen Pharmaceutica
- Kiadis
- Novartis
- Piramal Life Sciences
- Roche
- Schering-Plough
- Wyeth
| 
View Cart
